Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series Anews2026-08-11T12:00:44+00:00August 11th, 2026|Endpoints News|
BINSA legislation to limit biotech deals in China unveiled in Senatenews2026-08-07T16:35:22+00:00August 7th, 2026|Endpoints News|
China biotech will slow as it nears R&D frontier, Pfizer’s Baum predictsnews2026-08-07T15:00:01+00:00August 7th, 2026|Endpoints News|
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3news2026-08-06T06:56:05+00:00August 6th, 2026|Endpoints News|
In a first, WuXi AppTec surpasses Lonza’s six-month revenue news2026-08-05T17:59:02+00:00August 5th, 2026|Endpoints News|
Expedition gets another $115M for its twist on China NewCo modelnews2026-08-05T12:00:01+00:00August 5th, 2026|Endpoints News|
The China Debate: Biotech deserves a deeper discussionnews2026-08-04T18:20:59+00:00August 4th, 2026|Endpoints News|
Pathos does deals with AstraZeneca, China’s Alphamab, seeks up to $300M Series Enews2026-08-04T00:00:51+00:00August 4th, 2026|Endpoints News|
Work ethic becomes a flashpoint as China’s biotech pace quickensnews2026-08-03T14:00:18+00:00August 3rd, 2026|Endpoints News|
Merck CEO cautions Congress on imposing limits on Chinese dealmakingnews2026-07-23T14:53:43+00:00July 23rd, 2026|Endpoints News|
